The emergency department doctor does not play a role in obtaining consent from the next of kin for tissue or organ donation. Instead, it is important to involve the Specialist Nurse in Organ Donation (SNOD) as early as possible. The SNOD can provide valuable support and guidance to both the medical team and the family. They will assess the patient’s suitability for organ donation and approach the next of kin for consent, if appropriate. On the other hand, for tissue donation, a referral should be made to the tissue donation national referral centre. Retrievals can take place within 24 hours after death. In the UK, referrals can be made by phone to the tissue donation national referral centre (the contact number can be found in the notes below). It is important to note that the responsibility of gaining consent from the next of kin does not fall on the emergency department doctor.

Further Reading:

Cardiopulmonary arrest is a serious event with low survival rates. In non-traumatic cardiac arrest, only about 20% of patients who arrest as an in-patient survive to hospital discharge, while the survival rate for out-of-hospital cardiac arrest is approximately 8%. The Resus Council BLS/AED Algorithm for 2015 recommends chest compressions at a rate of 100-120 per minute with a compression depth of 5-6 cm. The ratio of chest compressions to rescue breaths is 30:2.

After a cardiac arrest, the goal of patient care is to minimize the impact of post cardiac arrest syndrome, which includes brain injury, myocardial dysfunction, the ischaemic/reperfusion response, and the underlying pathology that caused the arrest. The ABCDE approach is used for clinical assessment and general management. Intubation may be necessary if the airway cannot be maintained by simple measures or if it is immediately threatened. Controlled ventilation is aimed at maintaining oxygen saturation levels between 94-98% and normocarbia. Fluid status may be difficult to judge, but a target mean arterial pressure (MAP) between 65 and 100 mmHg is recommended. Inotropes may be administered to maintain blood pressure. Sedation should be adequate to gain control of ventilation, and short-acting sedating agents like propofol are preferred. Blood glucose levels should be maintained below 8 mmol/l. Pyrexia should be avoided, and there is some evidence for controlled mild hypothermia but no consensus on this.

Post ROSC investigations may include a chest X-ray, ECG monitoring, serial potassium and lactate measurements, and other imaging modalities like ultrasonography, echocardiography, CTPA, and CT head, depending on availability and skills in the local department. Treatment should be directed towards the underlying cause, and PCI or thrombolysis may be considered for acute coronary syndrome or suspected pulmonary embolism, respectively.

Patients who are comatose after ROSC without significant pre-arrest comorbidities should be transferred to the ICU for supportive care. Neurological outcome at 72 hours is the best prognostic indicator of outcome.

Here are some recommendations from NICE on how to manage breathlessness in the final days of life:

1. First, it is important to identify and treat any reversible causes of breathlessness in the person who is dying. This could include conditions like pulmonary edema or pleural effusion.

2. Non-pharmacological methods can also be considered for managing breathlessness in these individuals. It is not necessary to automatically start oxygen therapy for breathlessness. Oxygen should only be offered to those who are known or suspected to have low oxygen levels causing symptoms.

3. Breathlessness can be managed using medications such as opioids or benzodiazepines. These can be used individually or in combination, depending on the needs of the person.

For more detailed information, you can refer to the NICE guidance on the care of dying adults in the last days of life. https://www.nice.org.uk/guidance/ng31

An advance decision, also known as an advance directive in Scotland, is a statement made by a patient expressing their desire to refuse certain types of medical treatment or care in the event that they become unable to make or communicate decisions for themselves. These statements serve as a means of effectively communicating the patient’s wishes to healthcare professionals and family members, helping to avoid any confusion that may arise. If a patient reaches a point where they are no longer capable of making informed decisions about their care, an advance decision can provide clarity and guidance.

An advance decision can typically be utilized in the following situations: making decisions regarding CPR, determining the use of IV fluids and parenteral nutrition, deciding on specific procedures, and addressing the use of blood products for Jehovah’s Witnesses. However, it is important to note that advance decisions have their limitations and cannot be used to grant a relative lasting power of attorney, appoint a spokesperson to make decisions on the patient’s behalf, request a specific medical treatment, advocate for something illegal (such as assisted suicide), refuse treatment for a mental health condition, or authorize treatments that are not in the patient’s best interests.

A doctor is legally obligated to adhere to an advance decision unless certain circumstances arise. These circumstances include changes that invalidate the decision, advances or changes in treatment that alter the circumstances, ambiguity in the wording of the decision, or if the decision is unsigned or its authenticity is in doubt. If there are any doubts about the validity of an advance decision, it is advisable to seek legal advice. Unfortunately, there have been instances where advance decisions have been forged or signed under duress, and any suspicions of this nature should be raised.

It is important to note that there is no specific time period for which an advance decision remains valid.

An advanced decision is a legally binding document that allows individuals to express their preferences for end-of-life care in advance. It serves as a means of communication between patients, healthcare professionals, and family members, ensuring that the patient’s wishes are understood and respected. In situations where a patient becomes unable to make informed decisions about their care due to the progression of their illness, an advanced directive can help prevent any confusion or disagreements.

According to the General Medical Council (GMC), if there is a significant difference of opinion within the healthcare team or between the team and the patient’s loved ones regarding the patient’s care, it is advisable to seek advice or a second opinion from a colleague who has relevant expertise. In this particular case, it would be wise to consult a palliative care specialist to help resolve the disagreement between yourself and the patient’s wife.

For more information, you can refer to the GMC guidelines on treatment and care towards the end of life, which provide guidance on good practice in decision making.

There is no indication for an independent psychiatric evaluation of this patient. However, it is important to clearly document in his medical records that you have assessed his mental capacity and determined that he is capable of making decisions. It would not be appropriate in this case to refer him to a specialist against his wishes or to breach confidentiality by discussing his illness with his family or next of kin. According to the guidelines set by the General Medical Council (GMC), it is necessary to document the fact that the patient has declined relevant information. It is also important to avoid pressuring the patient to change their mind in these circumstances.

For further information, please refer to the GMC guidelines on treatment and care towards the end of life: good practice in decision making.

NICE recommends the use of octreotide for individuals in the final stages of life who are experiencing obstructive bowel disorders and have nausea or vomiting that does not improve within 24 hours of starting treatment with hyoscine butylbromide.

When managing nausea and vomiting in individuals nearing the end of life, it is important to assess the likely causes, such as certain medications, recent chemotherapy or radiotherapy, psychological factors, biochemical imbalances, raised intracranial pressure, gastrointestinal motility disorders, ileus, or bowel obstruction.

It is crucial to have discussions with the person who is dying and their loved ones about the available options for treating nausea and vomiting. Non-pharmacological methods should be considered as well.

When selecting medications to manage these symptoms, factors to consider include the likely cause and its reversibility, potential side effects (including sedation), other symptoms the person may be experiencing, the desired balance of effects when managing other symptoms, and compatibility and drug interactions with other medications the person is taking.

For individuals with obstructive bowel disorders who have nausea or vomiting, hyoscine butylbromide is recommended as the first-line pharmacological treatment. If symptoms do not improve within 24 hours of starting this treatment, octreotide should be considered.

For more information, please refer to the NICE guidance on the care of dying adults in the last days of life. https://www.nice.org.uk/guidance/ng31

An advance decision, also known as an advance directive in Scotland, is a statement made by a patient expressing their desire to refuse certain types of medical treatment or care in the event that they become unable to make or communicate decisions for themselves. These statements serve as a means of effectively communicating the patient’s wishes to healthcare professionals and family members, helping to avoid any confusion that may arise. If a patient reaches a point where they are no longer capable of making informed decisions about their care, an advance decision can provide clarity and guidance.

An advance decision can typically be utilized in the following situations: making decisions regarding CPR, determining the use of IV fluids and parenteral nutrition, deciding on specific procedures, and addressing the use of blood products for Jehovah’s Witnesses. However, it is important to note that advance decisions have their limitations and cannot be used to grant a relative lasting power of attorney, appoint a spokesperson to make decisions on the patient’s behalf, request a specific medical treatment, advocate for something illegal (such as assisted suicide), refuse treatment for a mental health condition, or authorize treatments that are not in the patient’s best interests.

A doctor is legally obligated to adhere to an advance decision unless certain circumstances arise. These circumstances include changes that invalidate the decision, advances or changes in treatment that alter the circumstances, ambiguity in the wording of the decision, or if the decision is unsigned or its authenticity is in doubt. If there are any doubts about the validity of an advance decision, it is advisable to seek legal advice. Unfortunately, there have been instances where advance decisions have been forged or signed under duress, and any suspicions of this nature should be raised.

It is important to note that there is no specific time period for which an advance decision remains valid.

When starting treatment with strong opioids for pain relief in palliative care, it is recommended to offer patients regular oral sustained-release or oral immediate-release morphine, depending on their preference. In addition, provide rescue doses of oral immediate-release morphine for breakthrough pain. For patients without renal or hepatic comorbidities, a typical total daily starting dose schedule of 20-30 mg of oral morphine is suggested, along with 5 mg of oral immediate-release morphine for rescue doses during the titration phase. It is important to adjust the dose until a good balance is achieved between pain control and side effects. If this balance is not reached after a few dose adjustments, it is advisable to seek specialist advice. Patients should be reviewed frequently, especially during the titration phase. For patients with moderate to severe renal or hepatic impairment, it is recommended to consult a specialist before prescribing strong opioids.

For maintenance therapy, oral sustained-release morphine is recommended as the first-line treatment for patients with advanced and progressive disease who require strong opioids. Transdermal patch formulations should not be routinely offered as first-line maintenance treatment unless oral opioids are not suitable. If pain remains inadequately controlled despite optimizing first-line maintenance treatment, it is important to review the analgesic strategy and consider seeking specialist advice.

When it comes to breakthrough pain, oral immediate-release morphine should be offered as the first-line rescue medication for patients on maintenance oral morphine treatment. Fast-acting fentanyl should not be offered as the first-line rescue medication. If pain continues to be inadequately controlled despite optimizing treatment, it may be necessary to seek specialist advice.

In cases where oral opioids are not suitable and analgesic requirements are stable, transdermal patches with the lowest acquisition cost can be considered. However, it is important to consult a specialist for guidance if needed. Similarly, for patients in whom oral opioids are not suitable and analgesic requirements are unstable, subcutaneous opioids with the lowest acquisition cost can be considered, with specialist advice if necessary.

For more information, please refer to the NICE Clinical Knowledge Summary: Opioids for pain relief in palliative care. https://www.nice.org.uk/guidance/cg140

When dealing with a terminally ill patient who is still lucid and alert and able to drink oral fluids, it is sensible to encourage them to take frequent sips of fluids to maintain hydration and alleviate symptoms of a dry mouth. According to NICE guidelines, it is important to support the dying person in their desire to drink if they are capable and willing. However, it is crucial to assess any difficulties they may have with swallowing or the risk of aspiration. It is recommended to have a discussion with the dying person and those involved in their care to weigh the risks and benefits of continuing to drink.

In addition, it is essential to provide regular care for the dying person’s mouth and lips, including managing dry mouth if necessary. This can involve assisting with teeth or denture cleaning if desired, as well as offering frequent sips of fluid. It is also encouraged to involve important individuals in the dying person’s life in providing mouth and lip care or giving drinks, if they are willing. Necessary aids should be provided, and guidance on safe drink administration should be given.

The hydration status of the dying person should be assessed on a daily basis, and the potential need for clinically assisted hydration should be reviewed while respecting the person’s wishes and preferences. It is important to discuss the risks and benefits of clinically assisted hydration with the dying person and their loved ones. It should be noted that while clinically assisted hydration may relieve distressing symptoms related to dehydration, it may also cause other problems. The impact on life extension or the dying process is uncertain whether hydration is provided or not.

Before initiating clinically assisted hydration, any concerns raised by the dying person or their loved ones should be addressed. An individualized approach should be taken into account, considering factors such as the person’s expressed preferences, cultural or religious beliefs, level of consciousness, swallowing difficulties, thirst level, risk of pulmonary edema, and the possibility of temporary recovery.

If the person exhibits distressing symptoms or signs associated with dehydration, such as thirst or delirium, and oral hydration is insufficient, a therapeutic trial of clinically assisted hydration may be considered. Monitoring for changes in symptoms or signs of dehydration, as well as any evidence of benefit or harm, should be conducted at least every 12 hours for those receiving clinically assisted hydration. If there are signs of clinical benefit, the hydration should be continued. However, if there are indications of potential harm, such as fluid overload, or if the person no longer desires it, the clinically assisted hydration should be stopped.

When starting treatment with strong opioids for pain relief in palliative care, it is recommended to offer patients regular oral sustained-release or oral immediate-release morphine, depending on their preference. In addition, provide rescue doses of oral immediate-release morphine for breakthrough pain. For patients without renal or hepatic comorbidities, a typical total daily starting dose schedule of 20-30 mg of oral morphine is suggested, along with 5 mg of oral immediate-release morphine for rescue doses during the titration phase. It is important to adjust the dose until a good balance is achieved between pain control and side effects. If this balance is not reached after a few dose adjustments, it is advisable to seek specialist advice. Patients should be reviewed frequently, especially during the titration phase. For patients with moderate to severe renal or hepatic impairment, it is recommended to consult a specialist before prescribing strong opioids.

For maintenance therapy, oral sustained-release morphine is recommended as the first-line treatment for patients with advanced and progressive disease who require strong opioids. Transdermal patch formulations should not be routinely offered as first-line maintenance treatment unless oral opioids are not suitable. If pain remains inadequately controlled despite optimizing first-line maintenance treatment, it is important to review the analgesic strategy and consider seeking specialist advice.

When it comes to breakthrough pain, oral immediate-release morphine should be offered as the first-line rescue medication for patients on maintenance oral morphine treatment. Fast-acting fentanyl should not be offered as the first-line rescue medication. If pain continues to be inadequately controlled despite optimizing treatment, it may be necessary to seek specialist advice.

In cases where oral opioids are not suitable and analgesic requirements are stable, transdermal patches with the lowest acquisition cost can be considered. However, it is important to consult a specialist for guidance if needed. Similarly, for patients in whom oral opioids are not suitable and analgesic requirements are unstable, subcutaneous opioids with the lowest acquisition cost can be considered, with specialist advice if necessary.

For more information, please refer to the NICE Clinical Knowledge Summary: Opioids for pain relief in palliative care. https://www.nice.org.uk/guidance/cg140